News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis B news

Show

From To
Hepatitis B
Ongoing hepatitis B virus replication associated with higher mortality for people with HIV

People with HIV and hepatitis B virus (HBV) co-infection have more than double the risk of death if they have ongoing high-level HBV replication, indicating a need for

Published
16 August 2016
By
Liz Highleyman
Hepatitis B
'Screen-and-treat' scheme for hepatitis B may prevent deadly complications

Research into Africa's first 'screen-and-treat' programme for hepatitis B suggests the initiative may reduce deadly complications of the virus. The new findings, from researchers at a number of international institutions including Imperial College London and the Medical Research Council Unit The Gambia, also suggest the initiative is feasible and cost-effective.

Published
27 July 2016
From
Eurekalert Inf Dis
Hepatitis B
Complete clearance of hepatitis B is rare - especially in women and people of Asian descent

Researchers at several different US sites have found that less than one-third of 1% of patients infected with hepatitis B virus (HBV) get rid of the virus per year, and overall, only 1.2% of patients finally get rid of it.

Published
12 July 2016
From
Eurekalert Inf Dis
Hepatitis B
HIV/HBV co-infection linked to worse immune recovery and death, but tenofovir improves outcomes

HIV-positive people with hepatitis B virus (HBV) co-infection had impaired CD4 cell recovery after starting antiretroviral therapy (ART) and a higher risk of death than those without

Published
23 May 2016
By
Liz Highleyman
Hepatitis B
Interferon-based therapy improves clinical outcomes in hepatitis delta infection

Patients with hepatitis delta virus infection treated with pegylated interferon alpha were less likely to develop clinical outcomes — like decompensation or hepatocellular carcinoma — compared with patients who received nucleos(t)ide based treatment or no treatment at all, according to a presentation at International Liver Congress.

Published
22 April 2016
From
Healio
Hepatitis B
Tenofovir alafenamide works well against hepatitis B with less effect on bones and kidneys

The new tenofovir alafenamide (TAF) pro-drug is as potent against hepatitis B virus (HBV) as the current tenofovir disoproxil fumarate (TDF) formulation, but with fewer detrimental effects

Published
18 April 2016
By
Liz Highleyman
Hepatitis B
ContraVir's CMX157 Outperforms Gilead's Tenofovir AF (TAF) Against Hepatitis B Virus in Independent Head-to-Head In-Vitro Study

Viral rebound studies showed that CMX157 demonstrates best-in-class duration of activity. Nine days following incubation with HBV, using two different experimental conditions, one at equimolar and one at EC90 concentrations, CMX157 showed two- to three-fold reduced viral rebound compared to TAF.

Published
30 March 2016
From
ContraVir press release
HIV testing policies and guidelines
Opt-out HIV/HBV/HCV testing for patients attending emergency departments identifies significant number of new infections

A week-long pilot study involving nine UK emergency departments has shown that routine, opt-out testing for HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) can

Published
22 March 2016
By
Michael Carter
Hepatitis B
Survey shows more than 800,000 people in US have hepatitis B, half of them Asian

Although nearly 70 million people in the US have been vaccinated against hepatitis B virus (HBV), there are still 847,000 people with evidence of infection, about 400,000

Published
22 February 2016
By
Liz Highleyman
Side-effects
D:A:D study: long-term treatment with tenofovir associated with increased risk of serious liver disease

Long-term therapy with the antiretroviral drug tenofovir increases the risk of end-stage liver disease and liver cancer, according to data from the D:A:D study published

Published
21 January 2016
By
Michael Carter
← Prev1...34567...19Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.